Clene Inc. Research and Development Expense
Clene Inc. (CLNN) reported Research and Development Expense of $3.47 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-14
- Clene Inc. research and development expense for the quarter ending 2026-06-30 was $3.47M, a 1.22% decline year-over-year.
- Clene Inc. research and development expense for the quarter ending 2026-03-31 was $329.00K, a 77.79% decline year-over-year.
- Clene Inc. research and development expense for the quarter ending 2025-12-31 was $5.50M, a 1.17% decline year-over-year.
- Clene Inc. research and development expense for the quarter ending 2025-09-30 was $3.51M, a 21.43% decline year-over-year.
- Clene Inc. research and development expense for fiscal 2025 was $14.01M, a 30.15% decline from fiscal 2024.
- Clene Inc. research and development expense for fiscal 2024 was $20.06M, a 24.75% decline from fiscal 2023.
- Clene Inc. research and development expense for fiscal 2023 was $26.66M, a 16.49% decline from fiscal 2022.
- Clene Inc. research and development expense for fiscal 2022 was $31.92M, a 12.33% increase from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $3.47M 10-Q · filed 2026-08-14 | $3.80M 10-Q · filed 2026-08-14 | $9.30M derived: sum of 3 quarters · filed 2026-08-14 | $12.82M derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | $329.00K 10-Q · filed 2026-05-14 | $5.83M derived: sum of 2 quarters · filed 2026-05-14 | $9.35M derived: sum of 3 quarters · filed 2026-05-14 | $12.86M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-12-31 | $5.50M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $9.02M derived: sum of 2 quarters · filed 2026-03-17 | $12.53M derived: sum of 3 quarters · filed 2026-08-14 | $14.01M 10-K · filed 2026-03-17 |
| 2025-09-30 | $3.51M 10-Q · filed 2025-11-13 | $7.03M derived: sum of 2 quarters · filed 2026-08-14 | $8.51M 10-Q · filed 2025-11-13 | $14.08M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-06-30 | $3.51M 10-Q · filed 2026-08-14 | $5.00M 10-Q · filed 2026-08-14 | $10.56M derived: sum of 3 quarters · filed 2026-08-14 | $15.03M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-03-31 | $1.48M 10-Q · filed 2026-05-14 | $7.05M derived: sum of 2 quarters · filed 2026-05-14 | $11.52M derived: sum of 3 quarters · filed 2026-05-14 | $15.67M derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | $5.57M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $10.04M derived: sum of 2 quarters · filed 2026-03-17 | $14.19M derived: sum of 3 quarters · filed 2026-03-17 | $20.06M 10-K · filed 2026-03-17 |
| 2024-09-30 | $4.47M 10-Q · filed 2025-11-13 | $8.62M derived: sum of 2 quarters · filed 2025-11-13 | $14.49M 10-Q · filed 2025-11-13 | $21.16M derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | $4.15M 10-Q · filed 2025-08-14 | $10.02M 10-Q · filed 2025-08-14 | $16.69M derived: sum of 3 quarters · filed 2025-08-14 | $22.66M derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | $5.87M 10-Q · filed 2025-05-07 | $12.54M derived: sum of 2 quarters · filed 2025-05-07 | $18.51M derived: sum of 3 quarters · filed 2025-05-07 | $25.13M derived: sum of 4 quarters · filed 2025-05-07 |
| 2023-12-31 | $6.67M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-24 | $12.64M derived: sum of 2 quarters · filed 2025-03-24 | $19.26M derived: sum of 3 quarters · filed 2025-03-24 | $26.66M 10-K · filed 2025-03-24 |
| 2023-09-30 | $5.97M 10-Q · filed 2024-11-13 | $12.59M derived: sum of 2 quarters · filed 2024-11-13 | $19.98M 10-Q · filed 2024-11-13 | $27.75M derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-06-30 | $6.62M 10-Q · filed 2024-08-07 | $14.01M 10-Q · filed 2024-08-07 | $21.78M derived: sum of 3 quarters · filed 2024-08-07 | $28.18M derived: sum of 4 quarters · filed 2024-08-07 |
| 2023-03-31 | $7.39M 10-Q · filed 2024-05-08 | $15.17M derived: sum of 2 quarters · filed 2024-05-08 | $21.57M derived: sum of 3 quarters · filed 2024-05-08 | $30.73M derived: sum of 4 quarters · filed 2024-05-08 |
| 2022-12-31 | $7.77M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-13 | $14.17M derived: sum of 2 quarters · filed 2024-03-13 | $23.34M derived: sum of 3 quarters · filed 2024-03-13 | $31.92M 10-K · filed 2024-03-13 |
| 2022-09-30 | $6.40M 10-Q · filed 2023-11-07 | $15.57M derived: sum of 2 quarters · filed 2023-11-07 | $24.15M 10-Q · filed 2023-11-07 | $33.67M derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-06-30 | $9.17M 10-Q · filed 2023-08-14 | $17.75M 10-Q · filed 2023-08-14 | $27.27M derived: sum of 3 quarters · filed 2023-08-14 | $33.41M derived: sum of 4 quarters · filed 2023-08-14 |
| 2022-03-31 | $8.58M 10-Q · filed 2023-05-12 | $18.10M derived: sum of 2 quarters · filed 2023-05-12 | $24.25M derived: sum of 3 quarters · filed 2023-05-12 | $30.72M derived: sum of 4 quarters · filed 2023-05-12 |
| 2021-12-31 | $9.52M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-13 | $15.67M derived: sum of 2 quarters · filed 2023-03-13 | $22.14M derived: sum of 3 quarters · filed 2023-03-13 | $28.42M 10-K · filed 2023-03-13 |
| 2021-09-30 | $6.15M 10-Q · filed 2022-11-07 | $12.62M derived: sum of 2 quarters · filed 2022-11-07 | $18.89M 10-Q · filed 2022-11-07 | $23.35M derived: sum of 4 quarters · filed 2022-11-07 |
| 2021-06-30 | $6.47M 10-Q · filed 2022-08-15 | $12.75M 10-Q · filed 2022-08-15 | $17.20M derived: sum of 3 quarters · filed 2022-08-15 | $21.20M derived: sum of 4 quarters · filed 2022-08-15 |
| 2021-03-31 | $6.28M 10-Q · filed 2022-05-09 | $10.73M derived: sum of 2 quarters · filed 2022-05-09 | $14.72M derived: sum of 3 quarters · filed 2022-05-09 | $18.28M derived: sum of 4 quarters · filed 2022-05-09 |
| 2020-12-31 | $4.45M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-11 | $8.45M derived: sum of 2 quarters · filed 2022-03-11 | $12.00M derived: sum of 3 quarters · filed 2022-03-11 | $15.20M 10-K · filed 2022-03-11 |
| 2020-09-30 | $3.99M 10-Q · filed 2021-11-08 | $7.55M derived: sum of 2 quarters · filed 2021-11-08 | $10.75M 10-Q · filed 2021-11-08 | |
| 2020-06-30 | $3.55M 10-Q · filed 2021-08-09 | $6.76M 10-Q · filed 2021-08-09 | ||
| 2020-03-31 | $3.20M 10-Q · filed 2021-05-10 | |||
| 2019-12-31 | $9.56M 10-K · filed 2021-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Serina Therapeutics, Inc. (SER) | United States | $0.054B | -2.35 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |
| Annovis Bio, Inc. (ANVS) | United States | $0.056B | -1.58 |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B | |
| NOMAD POWER SOLUTIONS, INC. (NMAD) | United States | $0.058B | |
| Boundless Bio, Inc. (BOLD) | United States | $0.059B | -0.88 |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| TALPHERA, INC. (TLPH) | United States | $0.060B |